Skip to content
Companies

NRX Pharmaceuticals

Drugs for suicidal bipolar depression and PTSD

Raised to date

$3.5M

of $3.5M offered across 1 Form D filing

Investors
2
Last filed
Mar 7, 2025

About

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for central nervous system disorders, with a particular focus on suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). The company seeks to fulfill significant unmet medical needs within these areas by delivering novel treatment options that promise enhanced efficacy and safety.

NRx Pharmaceuticals stands out with its breakthrough approach to treating severe psychiatric conditions through the modulation of the NMDA receptor, which offers a distinct mechanism of action compared to traditional therapies.

Funding

  • Option to acquireFiled Mar 7, 2025Form D
    $3.5M/ $3.5M

Product

NRX-101

Psychiatric Treatment

NRX-101 is an oral, fixed-dose combination therapy that incorporates D-cycloserine and lurasidone. It is specifically being developed for the treatment of suicidal bipolar depression and has received the esteemed FDA Breakthrough Therapy designation, which indicates its potential to offer significant improvements over existing treatment options.

  • Combination of D-cycloserine and lurasidone
  • Oral administration
  • FDA Breakthrough Therapy designation

Built for

Patients suffering from severe psychiatric conditions, especially those with suicidal ideation linked to bipolar depression.

People on file